Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2061-2069

  Alt, Silke ^a   Mitchenall, Lesley A ^b   Maxwell, Anthony ^b   Heide, Lutz ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NORWICH RESEARCH PARK   (United Kingdom)

Author keywords

Decatenation assays; MICs; Potassium glutamate; Supercoiling assays

Indexed keywords

AMINOCOUMARIN DERIVATIVE; ANTIBIOTIC AGENT; CLOROBIOCIN; COUMAMYCIN A1; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GLUTAMATE POTASSIUM; GLUTAMATE SODIUM; NOVCLOBIOCIN 101; NOVCLOBIOCIN 102; NOVCLOBIOCIN 103; NOVCLOBIOCIN 105; NOVCLOBIOCIN 217; NOVCLOBIOCIN 225; NOVOBIOCIN; SIMOCYCLINONE D8; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; COMPARATIVE STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; IC 50; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; STAPHYLOCOCCUS AUREUS;

AMINOCOUMARINS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CLONING, MOLECULAR; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, SUPERHELICAL; ESCHERICHIA COLI; GLUTAMATES; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM GLUTAMATE; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE INHIBITORS;

EID: 80051684987     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr247     Document Type: Article

References (40)

1. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001; 70: 369-413.
2. Schoeffler AJ, Berger JM. Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem Soc Trans 2005; 33: 1465-70.
3. Maxwell A, Lawson DM. The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 2003; 3: 283-303.
4. Oblak M, Kotnik M, Solmajer T. Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem 2007; 14: 2033-47.
5. Tse-Dinh YC. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect Disord Drug Targets 2007; 7: 3-9.
6. WHO/EDM/PAR/2004.7. Priority Medicines for Europe and the World. 2004. http://whqlibdoc.who.int/hq/2004/WHO_EDM_PAR_2004.7.pdf (29 April 2011, date last accessed).
7. Bates AD, Maxwell A. Energy coupling in type II topoisomerases: why do they hydrolyze ATP? Biochem 2007; 46: 7929-41.
8. Heide L. The aminocoumarins: biosynthesis and biology. Nat Prod Rep 2009; 26: 1241-50.
9. Lewis RJ, Singh OMP, Smith CV et al. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J 1996; 15: 1412-20.
10. Bellon S, Parsons JD, Wei Y et al. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob Agents Chemother 2004; 48: 1856-64.
11. Edwards MJ, Flatman RH, Mitchenall LA et al. A crystal structure of the bifunctional antibiotic simocyclinone D8, bound to DNA gyrase. Science 2009; 326: 1415-8.
12. Flatman RH, Howells AJ, Heide L et al. Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action. Antimicrob Agents Chemother 2005; 49: 1093-100.
13. Oppegard LM, Hamann BL, Streck KR et al. In vivo and in vitro patterns of the activity of simocyclinone D8, an angucyclinone antibiotic from Streptomyces antibioticus. Antimicrob Agents Chemother 2009; 53: 2110-9.
14. Blanche F, Cameron B, Bernard FX et al. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother 1996; 40: 2714-20.
15. Hiasa H, Shea ME, Richardson CM et al. Staphylococcus aureus gyrase-quinolone-DNA ternary complexes fail to arrest replication fork progression in vitro. Effects of salt on the DNA binding mode and the catalytic activity of S. aureus gyrase. J Biol Chem 2003; 278: 8861-8.
16. Flatman RH, Eustáquio A, Li SM et al. Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis. Antimicrob Agents Chemother 2006; 50: 1136-42.
17. Heide L. Aminocoumarins mutasynthesis, chemoenzymatic synthesis, and metabolic engineering. Meth Enzymol 2009; 459: 437-55.
18. Heide L. Genetic engineering of antibiotic biosynthesis for the generation of new aminocoumarins. Biotechnol Adv 2009; 27: 1006-14.
19. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual, 3rd edn. New York: Cold Spring Harbor Laboratory Press, 2001.
20. Anderle C, Hennig S, Kammerer B et al. Improved mutasynthetic approaches for the production of modified aminocoumarin antibiotics. Chem Biol 2007; 14: 955-67.
21. Eustáquio AS, Gust B, Luft T et al. Clorobiocin biosynthesis in Streptomyces. Identification of the halogenase and generation of structural analogs. Chem Biol 2003; 10: 279-88.
22. Xu H, Kahlich R, Kammerer B et al. CloN2, a novel acyltransferase involved in the attachment of the pyrrole-2-carboxyl moiety to the deoxysugar of clorobiocin. Microbiology 2003; 149: 2183-91.
23. Luria SE, Burrous JW. Hybridization between Escherichia coli and Shigella. J Bacteriol 1957; 74: 461-76.
24. Maxwell A, Howells AJ. Overexpression and purification of bacterial DNA gyrase. In: Bjornsti M-A, Osheroff N, eds. DNA Topoisomerase Protocols, I: DNA Topology and Enzymes, vol. 94. Totowa: Humana Press, 1999; 135-44.
25. Wiegand I, Hilpert K, Hancock REW. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nature Prot 2008; 3: 163-75.
26. Morgan-Linnell SK, Hiasa H, Zechiedrich L et al. Assessing sensitivity to antibacterial topoisomerase II inhibitors. Curr Protoc Pharmacol 2007; 39: 3.13.1-26.
27. Pan XS, Fisher LM. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob Agents Chemother 1999; 43: 1129-36.
28. Saiki AYC, Shen LL, Chen CM et al. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones. Antimicrob Agents Chemother 1999; 43: 1574-7.
29. Strahilevitz J, Robicsek A, Hooper DC. Role of the extended a4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones. Antimicrob Agents Chemother 2006; 50: 600-6.
30. Hu X, Machius M, Yang W. Monovalent cation dependence and preference of GHKL ATPases and kinases. FEBS Lett 2003; 544: 268-73.
31. Peng H, Marians KJ. Decatenation activity of topoisomerase IV during oriC and pBR322 DNA replication in vitro. Proc Natl Acad Sci USA 1993; 90: 8571-5.
32. Takei M, Fukuda H, Kishii R et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2001; 45: 3544-7.
33. Tanaka M, Onodera Y, Uchida Y et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 2362-6.
34. Fujimoto-Nakamura M, Ito H, Oyamada Y et al. Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 3810-5.
35. Anderle C, Stieger M, Burrell M et al. Biological activities of novel gyrase inhibitors of the aminocoumarin class. Antimicrob Agents Chemother 2008; 52: 1982-90.
36. Sissi C, Marangon E, Chemello A et al. The effects of metal ions on the structure and stability of the DNA gyrase B protein. J Mol Biol 2005; 353: 1152-60.
37. Galm U, Heller S, Shapiro S et al. Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis. Antimicrob Agents Chemother 2004; 48: 1307-12.
38. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem 2003; 3: 249-82.
39. van der Auwera P, Vandermies A, Grenier P et al. Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria. Drugs Exp Clin Res 1987; 13: 125-32.
40. Vickers AA, O'Neill AJ, Chopra I. Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies. J Antimicrob Chemother 2007; 60: 269-73.